ANDA 215393, held by Padagis Israel. Tazarotene.
As of Nov 15, 2026, ANDA 215393 (Tazarotene), held by Padagis Israel, was first approved by FDA on Jul 29, 2025, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 29, 2025 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tazarotene0.045% ยท lotion;topical | Tazarotene | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
